(3S,8R,9S,10R,13S,14S,17Z)-17-hydroxyimino-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-ol | 2830-48-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (3S,8R,9S,10R,13S,14S,17Z)-17-hydroxyimino-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-ol
• CAS: 2830-48-0
• 化学式: C₁₉H₂₉NO₂
• 分子量: 303.4
• InChiKey: WNJVMVZIGIACNN-HNOINMFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  52.8
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3BETA-OL
  申请人：Bhardwaj Tilak Raj

  公开号：US20100292201A1

  公开（公告）日：2010-11-18

  The present invention relates to steroidal esters of 17-oximino-5-androsten-3-ol, of compound of general formula (A) wherein R is selected from a group consisting of arylalkyl, aryl, substituted aryl. The ester derivatives are synthesized starting from Dehydroandrosterone acetate. The compounds were tested for their antiproliferative activity and 5α-reductase inhibitory activity in comparison to Finasteride. Decreased androgen level have been found in serum of animal treated with newly synthesized compounds. These compounds have also shown better cytotoxicity in comparison to reference drug Finasteride. Thus such compounds can be useful in treatment of androgen dependent disorder of prostate alone or by synergistic effect they can decrease the size of prostate due to their antiproliferative activity.

  本发明涉及17-氧代氨基-5-雄烯-3-醇的类固醇酯化合物，通式（A）中R选自芳基烷基、芳基、取代芳基的群。酯衍生物是从去氢雄烯酮醋酸酯开始合成的。与非那雄胺相比，这些化合物被测试其抗增殖活性和5α-还原酶抑制活性。发现动物血清中的雄激素水平降低，这些动物接受了新合成化合物的治疗。与参考药物非那雄胺相比，这些化合物还表现出更好的细胞毒性。因此，这些化合物可以在治疗仅限于前列腺雄激素依赖性疾病中发挥作用，或者通过协同作用减小前列腺的大小，因为它们具有抗增殖活性。
• NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3 BETA-OL
  申请人：Council of Scientific & Industrial Research

  公开号：EP2188301A2

  公开（公告）日：2010-05-26
• US8435975B2
  申请人：——

  公开号：US8435975B2

  公开（公告）日：2013-05-07
• [EN] NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3ß-OL<br/>[FR] NOUVEAUX ESTERS STÉROÏDIENS DE 17-OXIMO-5-ANDROSTÈNE-3?-OL
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2009027994A2

  公开（公告）日：2009-03-05

  The present invention relates to steroidal esters of 17-oximino -5-androsten-3-ol,of compound of general formula (A) wherein R is selected form a group consisting of arylalkyl, aryl, substituted aryl. The ester derivatives are synthesized starting from Dehydroandrosterone acetate. The compounds were tested for their antiproliferative activity and 5α-reductase inhibitory activity in comparison to Finasteride. Decreased androgen level have been found in serum of animal treated with newly synthesized compounds. These compounds have also shown better cytotoxicity in comparison to reference drug Finasteride. Thus such compounds can be useful in treatment of androgen dependent disorder of prostate alone or by synergistic effect they can decrease the size of prostate due to their antiproliferative activity.